Is Ustekinumab currently officially on the market in China?
Ustekinumab (Ustekinumab) is a humanized monoclonal antibody mainly used to treat immune-mediated diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In recent years, with the widespread application of biological agents in the fields of rheumatism, immunity and digestion, the efficacy of ustekinumab has been widely recognized and has been included in standard treatment plans in many countries.
At present, ustekinumab has been officially approved for marketing in China and has been included in the National Medical Insurance Drug List. This means that domestic patients can use the drug after being prescribed it through regular hospitals or pharmacies, greatly improving the accessibility of treatment. Medical insurance coverage has also reduced the financial burden for many long-term treatment patients, making the drug no longer limited to a few people.
In terms of price, ustekinumab, as an imported biological agent, is priced relatively high. There are differences in prices for different specifications (such as 45mg/0.5ml or 90mg/1ml ). After reimbursement according to the medical insurance policy, the patient's out-of-pocket payment ratio is significantly reduced. Taking the 90mg injection form as an example, the price before medical insurance may be more than 10,000 yuan. However, after being included in medical insurance, depending on the regional reimbursement ratio, the actual out-of-pocket payment may be reduced to 3,000 yuan or even lower. The specific amount needs to be announced by the local hospital or the medical insurance bureau.
In general, the official launch and medical insurance coverage of ustekinumab in China provide new treatment hope for the majority of patients with immune-related diseases. If patients need to use this drug, it is recommended that they go to the rheumatology and immunology department or gastroenterology department of a regular tertiary hospital, and reasonably arrange the medication plan according to the doctor's recommendations. At the same time, consult the local medical insurance policy to obtain the most accurate cost information.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)